share_log

Vivos Therapeutics | EFFECT: Others

Vivos Therapeutics | EFFECT: Others

Vivos Therapeutics | EFFECT：其他
美股sec公告 ·  04/29 06:14
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.
Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.
在美國上市的公司Vivos Therapeutics, Inc. 取得了重要的里程碑，美國證券交易委員會（SEC）宣佈其S-1表格自2024年4月26日下午 4:30 起生效。S-1表格是公司在繼續向公衆出售證券之前必須向美國證券交易委員會提交的註冊聲明。該表格的有效性表明，Vivos Therapeutics已滿足美國證券交易委員會規定的所有監管要求，爲潛在的公開募股或其他證券相關活動鋪平了道路。
在美國上市的公司Vivos Therapeutics, Inc. 取得了重要的里程碑，美國證券交易委員會（SEC）宣佈其S-1表格自2024年4月26日下午 4:30 起生效。S-1表格是公司在繼續向公衆出售證券之前必須向美國證券交易委員會提交的註冊聲明。該表格的有效性表明，Vivos Therapeutics已滿足美國證券交易委員會規定的所有監管要求，爲潛在的公開募股或其他證券相關活動鋪平了道路。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息